Abstract:Background The efficacy of topical minoxidil (MX) alone on female pattern hair loss (FPHL) is limited. Combination therapy based on topical MX is currently expected to provide better outcomes. Objectives This study aimed to assess whether the combined therapies including MX plus oral spironolactone (SPT) and MX plus microneedling (MN) have advantages in efficacy and safety over topical MX alone on mild-to-moderate FPHL with normal hormone levels in the blood and regular menstrual cycle. Methods A prospective, single-center, parallel-group, evaluator blinded, randomized trial including 120 non-menopause women with proven FPHL (Sinclair class II-III) was performed in China. Patients were randomly assigned to three groups, namely, the MX group (5% topical MX alone, once daily), the MX + SPT group (MX plus SPT 80–100 mg daily), and the MX+MN group (MX plus MN every 2 weeks, 12 sessions). The change from the baseline to week 24 was assessed in hair growth (hair density and diameter under dermoscope), scalp tissue structure (epidermal thickness, dermis thickness, and average hair follicle diameter under ultrasound biomicroscopy), physician's global assessment (using a 7-point global-assessment scale and Sinclair's stage change), patient evaluation (Women's Androgenetic Alopecia Quality of Life Questionnaire and Sinclair's hair-shedding score) and side effects. Results In total, 115 participants completed the trial. At week 24, the hair density increased most in MX + MN group and increased least in MX group ( p < 0.001 for MX + MN group vs. MX + SPT group; p = 0.009 for MX + SPT group vs. MX group). The hair shaft diameter significantly increased in all groups ( p < 0.001, respectively), but there were no significant differences among the three groups ( p = 0.905). The epidermal thickness and average hair follicle diameter only increased in MX + MN group. Dermis thickness increased in all groups, but there were no significant differences among the three groups. Both physician's and patient assessments showed improvement in all three groups. Scalp pruritus was the most common side effect. The MX + SPT group had the most reported adverse effects. Limitations The main limitations of this study are the relatively small sample size, the exclusion of severe FPHL patients, and the potential bias from unblinded treatments among the 3 groups. Conclusion Topical MX combined with MN is a better choice than either MX plus oral SPT or MX alone for the treatment of mild-to-moderate FPHL patients.

"Miliacin encapsulated by polar lipids stimulates cell proliferation in hair bulb and improves telogen effluvium in women"

Efficacy of a wheat polar lipid complex in reducing hair loss and improving hair growth in healthy women: A randomized, double-blind, placebo-controlled clinical study

New Plant Extracts Exert Complementary Anti‐Hair Loss Properties in Human In Vitro and Ex Vivo Models

Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial

Efficacy of Cistanche Tubulosa and Laminaria Japonica Extracts (MK-R7) Supplement in Preventing Patterned Hair Loss and Promoting Scalp Health

Evaluation of efficacy of Silybum marianum flower extract on the mitigating hair loss in vitro and in vivo

Effects of the Complex of Panicum miliaceum Extract and Triticum aestivum Extract on Hair Condition

A Six-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Women With Self-Perceived Thinning Hair

Application of mevalonolactone prevents deterioration of epidermal barrier function by accelerating the lamellar granule lipid transport system

Efficacy and Safety of a New Topical Hair Loss-Lotion Containing Oleanolic Acid, Apigenin, Biotinyl Tripeptide-1, Diaminopyrimidine Oxide, Adenosine, Biotin and Ginkgo biloba in Patients with Androgenetic Alopecia and Telogen effluvium: A Six-month Open-Label Prospective Clinical Study

Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial

Split-scalp pilot study to evaluate effectiveness of Minoxidil 0,5% MMP® versus Topical Minoxidil 5% in the treatment of Female Pattern Hair Loss

A Long-Term Study of the Safety and Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Perimenopausal, Menopausal, and Postmenopausal Women

Effect of a sphingolipid-mimetic compound on the promotion of hair growth: A randomized, double-blind, placebo-controlled clinical trial

Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic treatment

Efficacy and safety of combined topical ethinylestradiol with minoxidil versus topical minoxidil in female pattern hair loss. A trichoscopic randomized controlled clinical study

Polygonum multiflorum extract support hair growth by elongating anagen phase and abrogating the effect of androgen in cultured human dermal papilla cells

Comparative efficacy of topical minoxidil alone against combination of topical minoxidil and platelet rich plasma in women with female pattern hair loss—A pilot, open randomised trial

Vitamins and their derivatives synergistically promote hair shaft elongation ex vivo via PlGF/VEGFR-1 signalling activation

A Well‐Tolerated Hair Serum Containing New Natural Active Ingredients Reduced Hair Loss and Improved Quality of Life in Women With Chronic Telogen Effluvium: A 16‐Week Controlled Study

Effect of applying Lactiplantibacillus plantarum subsp. plantarum N793 to the scalps of men and women with thinning hair: a randomized, double-blind, placebo-controlled, parallel-group study